Abbisko Cayman Dividenden en inkoop

Dividend criteriumcontroles 0/6

Abbisko Cayman heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

2.6%

Terugkoop Rendement

Totaal aandeelhoudersrendement	2.6%
Toekomstig dividendrendement	0%
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente updates van dividend en inkoop

Recent updates

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

Sep 30

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Apr 27

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Jan 09

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Nov 01

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Jun 08

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van 2256 in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van 2256 zijn gestegen.

Dividendrendement versus markt

Abbisko Cayman Dividendrendement versus markt

Hoe verhoudt 2256 dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (2256)	n/a
Markt onderkant 25% (HK)	3.2%
Markt Top 25% (HK)	8.0%
Gemiddelde industrie (Biotechs)	1.1%
Analist prognose (2256) (tot 3 jaar)	0%

Opmerkelijk dividend: Het dividendrendement van 2256 kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van 2256 kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio 2256 te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat 2256 geen uitbetalingen heeft gerapporteerd.

Abbisko Cayman Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Recent updates

Consensus EPS estimates fall by 45%

Abbisko Cayman Limited Announces Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Companies Like Abbisko Cayman (HKG:2256) Can Afford To Invest In Growth

First half 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.32 loss in 1H 2023)

Abbisko Cayman Limited to Report First Half, 2024 Results on Aug 12, 2024

Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib (ABSK011) in Combination with Atezolizumab for the 2024 Esmo-Gi Congress

Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation

Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary

Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

Founder recently bought HK$358k worth of stock

Consensus revenue estimates decrease by 37%

Consensus EPS estimates fall by 89%

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Abbisko Cayman Limited, Annual General Meeting, Jun 18, 2024

Abbisko Cayman Limited to Report Fiscal Year 2023 Results on Mar 12, 2024

An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued

Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib (ABSK021) in China

Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051

Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting

Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?

Founder recently bought HK$257k worth of stock

Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology

Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa

Founder recently bought HK$121k worth of stock

Consensus revenue estimates increase by 2,172%

Abbisko Cayman Limited to Report First Half, 2023 Results on Aug 15, 2023

Abbisko Cayman Limited Announces Resignation of Dr. XIA Gavin Guoyao as Non-Executive Director

Abbisko Therapeutics Co., Ltd. to Present the Updated Clinical Phase Ib Data of Pimicotinib (ABSK021)

US FDA Grants Breakthrough Therapy Designation for CSF-1R Inhibitor Pimicotinib(ABSK021) of Abbisko Therapeutics

Less than half of directors are independent

Abbisko Therapeutics Co., Ltd. Completed the Dosing of the First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

Abbisko Cayman Limited Appoints Zhang Zidong as Chief Financial Officer

Less than half of directors are independent

Consensus forecasts updated

Key Executive recently bought HK$1.1m worth of stock

Less than half of directors are independent

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend